(195 days)
Not Found
No
The description focuses on electrical stimulation and user-controlled intensity, with no mention of AI/ML algorithms for treatment personalization, prediction, or analysis.
Yes
The device is indicated for the acute treatment of migraine with or without aura, delivering electrical pulses to alleviate symptoms, which is a therapeutic action.
No
The device is indicated for acute treatment of migraine and delivers electrical pulses. Its purpose is therapeutic intervention, not diagnosis.
No
The device description explicitly states it includes hardware components: a wearable armband, electronic circuitry, a battery, and electrodes. While it is controlled by software, it is not solely software.
Based on the provided information, the Nerivio Migra is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is for the acute treatment of migraine. This is a therapeutic purpose, not a diagnostic one.
- Device Description: The device delivers electrical pulses to the upper arm. This is a form of physical therapy or neuromodulation, not a method for examining specimens from the human body.
- Mechanism of Action: The device works by delivering electrical stimulation, not by analyzing biological samples or performing tests on them.
- Performance Studies: The performance studies evaluate the effectiveness of the treatment in reducing migraine symptoms, not the accuracy of a diagnostic test. The metrics reported are related to treatment response (pain reduction, pain-free status), not diagnostic performance (sensitivity, specificity, etc.).
IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. The Nerivio Migra does not perform any such function. It is a therapeutic device.
N/A
Intended Use / Indications for Use
The Nerivio Migra is indicated for acute treatment of migraine with or without aura in patients 18 years of age or older who do not have chronic migraine. It is a prescription use, selfadministered device for use in the home environment at the onset of migraine headache or aura.
Product codes
QGT
Device Description
The Nerivio Migra is a wearable, battery-powered device that is controlled by a mobile application. The system delivers low energy electrical pulses to the upper arm for 45 minutes per treatment, after which the device turns off automatically.
The device hardware consists of an armband intended to be worn on a user's upper arm. The armband contains the electronic circuitry and the battery in a plastic storage case as well as two electrodes that are attached to the interior of the armband and placed against the user's skin.
The device is operated and controlled via software that is installed and run on a user's personal mobile device such as a mobile phone or tablet. The device hardware communicates with the mobile application through a Bluetooth protocol. This mobile application software allows the user to control the stimulation intensity from 0 to 100% (representing intensity levels of 0-40mA), to start or stop the stimulation program, and to view device status such as the device's connection state, a progress bar for stimulation duration, battery level, and user notifications.
The patient is instructed to adjust the intensity to the strongest stimulation level below the perceived pain level. Treatments with Nerivio Migra are intended to be self-administered by the user immediately after the onset of migraine headache or aura.
The basic pulse structure is biphasic, with symmetrical interleaving phases and rectangular shape. The amplitude shift signal alternates between a nominal maximum and a nominal minimum of the amplitude signal. The maximal output current is 40mA. The assumed impedance is 1K ohm +/- 500 ohms.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
upper arm
Indicated Patient Age Range
18 years of age or older
Intended User / Care Setting
self-administered device for use in the home environment
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The 252-subject pivotal study was a prospective, one-to-one randomized, double-blind, sham controlled multi-center study to evaluate the effectiveness and safety of Nerivio Migra.
The primary outcome measure was the percentage of participants reporting a reduction in their pain level without use of medication from severe or moderate to mild or no pain or from mild to no pain within 2 hours in the "test treatment" excluding the run-in treatment which was the first in-study migraine attack.
Secondary endpoints measured include: MBS relief at 2 hours post-treatment, headache relief and MBS relief at 2 hours post-treatment, MBS disappearance 2 hours post-treatment, and headache disappearance 2 hours post-treatment.
The ITT analysis set included all participants who were randomized. The mITT analysis set included all participants who were randomized and treated at least one attack (excluding the run-in test attack) within 1 hour from the attack onset. The PP analysis set included participants who were randomized and for whom the first qualified attack (excluding the "run-in" test attack) conformed with the protocol instructions.
The ITT analysis set served as the main set for safety assessments. The mITT analysis set was used for all effectiveness assessments. The primary and secondary effectiveness assessments were performed on the mITT analysis set and also on the PP and ITT analysis sets as a sensitivity analysis.
A total of 296 participants were recruited; 252 were randomized (126 to active group, 126 to sham group). 237 participants completed at least one treatment (run-in treatment), and 202 completed the test treatment within one hour from symptom onset and reported pain at 2 hours.
For the primary endpoint in the mITT analysis set, 66.7% (66/99) in the active group achieved pain-reduction response 2 hours after treatment, compared to 38.8% (40/103) in the sham group (p
§ 882.5899 Trunk and limb electrical stimulator to treat headache.
(a)
Identification. A trunk and limb electrical stimulator to treat headache is a device intended to treat headache through the application of electrical stimulation anywhere on the body of the patient apart from the patient's head or neck through electrodes placed on the skin. The stimulation may be provided transcutaneously or percutaneously.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. This testing must include:
(i) Characterization of the electrical stimulation, including the following: Waveforms; output modes; maximum output voltage and maximum output current (at 500Ω, 2kΩ, and 10kΩ loads); pulse duration; frequency; net charge per pulse; and maximum phase charge, maximum current density, maximum average current, and maximum average power density (at 500Ω);
(ii) Characterization of the impedance monitoring system; and
(iii) Characterization of the electrode performance including the electrical performance, adhesive integrity, shelf-life, reusability, and current distribution of the electrode surface area.
(2) The patient-contacting components of the device must be demonstrated to be biocompatible.
(3) Performance testing must demonstrate electromagnetic compatibility and electrical, mechanical, and thermal safety in the intended use environment.
(4) Software verification, validation, and hazard analysis must be performed.
(5) Labeling must include the following:
(i) Instructions for use, including the typical sensations experienced during treatment;
(ii) A detailed summary of the electrical stimulation output, and the device technical parameters, including any wireless specifications;
(iii) A shelf life for the electrodes and reuse information; and
(iv) Instructions on care and cleaning of the device.
0
DE NOVO CLASSIFICATION REQUEST FOR NERIVIO MIGRA
REGULATORY INFORMATION
FDA identifies this generic type of device as:
Trunk and limb electrical stimulator to treat headache. A trunk and limb electrical stimulator to treat headache is a device intended to treat headache through the application of electrical stimulation anywhere on the body of the patient apart from the patient's head or neck through electrodes placed on the skin. The stimulation may be provided transcutaneously or percutaneously.
NEW REGULATION NUMBER: 21 CFR 882.5899
CLASSIFICATION: Class II
PRODUCT CODE: QGT
BACKGROUND
DEVICE NAME: Nerivio Migra
SUBMISSION NUMBER: DEN180059
DATE OF DE NOVO: November 6, 2018
Theranica Bio-Electronics LTD. CONTACT: 45 Ha-Melakha St. Netanya, Israel 4250574
INDICATIONS FOR USE
The Nerivio Migra is indicated for acute treatment of migraine with or without aura in patients 18 years of age or older who do not have chronic migraine. It is a prescription use, selfadministered device for use in the home environment at the onset of migraine headache or aura.
LIMITATIONS
The sale, distribution, and use of the Nerivio Migra are restricted to prescription use in accordance with 21 CFR 801.109.
The safety and effectiveness of the device has not been demonstrated for subjects with chronic migraine.
The safety and effectiveness of the device has not been demonstrated for the preventive treatment of migraine headache.
1
The device should not be used by people with congenital heart failure (severe cardiac or cerebrovascular disease.
The device should not be used by people with uncontrolled epilepsy.
The device should not be used by people with active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device. Such use could cause electric shock, electrical interference or serious injuries or medical conditions.
The device has not been evaluated for use in pregnant women and people less than 18 years of age.
Please refer to the labeling for a more complete list of contraindications, warnings, and precautions.
DEVICE DESCRIPTION
The Nerivio Migra is a wearable, battery-powered device that is controlled by a mobile application. The system delivers low energy electrical pulses to the upper arm for 45 minutes per treatment, after which the device turns off automatically.
The device hardware consists of an armband intended to be worn on a user's upper arm. The armband contains the electronic circuitry and the battery in a plastic storage case as well as two electrodes that are attached to the interior of the armband and placed against the user's skin.
The device is operated and controlled via software that is installed and run on a user's personal mobile device such as a mobile phone or tablet. The device hardware communicates with the mobile application through a Bluetooth protocol. This mobile application software allows the user to control the stimulation intensity from 0 to 100% (representing intensity levels of 0-40mA), to start or stop the stimulation program, and to view device status such as the device's connection state, a progress bar for stimulation duration, battery level, and user notifications.
The patient is instructed to adjust the intensity to the strongest stimulation level below the perceived pain level. Treatments with Nerivio Migra are intended to be self-administered by the user immediately after the onset of migraine headache or aura.
The basic pulse structure is biphasic, with symmetrical interleaving phases and rectangular shape. The amplitude shift signal alternates between a nominal maximum and a nominal minimum of the amplitude signal. The maximal output current is 40mA. The assumed impedance is 1K ohm +/- 500 ohms.
Output parameters and other electrical specifications of the Nerivio Migra are presented below in Table 1.
2
| Parameter | Specification |
|---|---|
| Number of channels | 1 |
| Waveform | Biphasic rectangular, modulated |
| Net Charge (μC per pulse) | 0 (charge is balanced using a symmetrical, biphasic pulse) |
| Max output voltage | |
| 500Ω | 20V (measured) |
| 2KΩ | 60V (measured) |
| 10KΩ | 60V (measured) |
| Max output current | |
| 500Ω | 40mA |
| 2KΩ | 30mA |
| 10KΩ | 6mA |
| Maximum phase charge (500Ω) | 8μC |
| Maximum average current (500Ω) | 1.76mA |
| Maximum current density (peak) (500Ω) | 1.6mA/cm² |
| Maximum current density (r.m.s) (500Ω) | 0.34mA/cm |
| Maximum average current density (abs value) (500Ω) | 0.07mA/cm² |
| Maximum average power density (500Ω) | 1.41mW/cm² |
| Frequency | 100-120Hz, average 110Hz (measured) |
| Primary phase duration [μSec] | 200 |
| Pulse Duration [μSec] | 400 |
| Burst mode | No |
| Program duration [min] | 45 |
| Electrode Area | 25cm² |
3
| Electrode
compliance with
| 21 CFR 898 | Yes | |
|---|---|---|
| Electrode cable | No | |
| Indication | ||
| Display | Device LED, on/off | |
| switch | Mobile Application | |
| - On/off status | - Yes (LED, switch | |
| position) | - No | |
| - Wireless | ||
| connection | - Yes | - Yes |
| - Low battery | - No | - Yes (stimulation intensity) |
| - Current level | - No | - Yes (stimulation time bar) |
| - Output mode | - Yes | - Yes (stimulation time bar) |
| - Time to cut-off | - No | |
| Power Source | Lithium ion battery | |
| Operating time: 360 minutes (8 treatments of 45 min) | ||
| Processor control | Yes | |
| Wireless control | Yes | |
| Automatic | ||
| overload trip | Yes, limiter for max current and voltage | |
| Automatic no | ||
| load trip | Yes, out-of-range load detection | |
| Automatic shut | ||
| off | Yes, timer | |
| Stimulation | ||
| intensity control | Yes, current amplitude is adjusted by the user |
Table 1: Nerivio Migra output parameters
SUMMARY OF NONCLINICAL/BENCH STUDIES
BIOCOMPATIBILITY/MATERIALS
The Nerivio Migra is connected to the patient's intact skin for a treatment period of 45 minutes. The skin-contacting components of the Nerivio Migra are the following:
Electrodes with hydrogel that have been FDA cleared through K130987 ● (b) (4)
The Nerivio Migra has demonstrated biocompatibility by design because these off-theshelf devices have been previously evaluated for cytotoxicity, irritation and sensitization, per ISO 10993-1 "Biological evaluation of medical devices -- Part 1: Evaluation and testing within a risk management process" and per recommendations in FDA's guidance document entitled, "Use of International Standard ISO 10993-1, "Biological evaluation of
4
medical devices - Part 1: Evaluation and testing within a risk management process." All results demonstrated acceptable performance.
SHELF LIFE AND STERILITY
The Nerivio Migra has a shelf life of 9 months.
There are no sterilization requirements for the marketed device and the user does not sterilize the device before first or repeat uses. The electrodes are non-sterile and designed for multiple usages. The electrode cover is reusable. Cleaning and maintenance instructions for the device are included in the labeling.
ELECTROMAGNETIC COMPATIBILITY AND ELECTRICAL SAFETY
The Nerivio Migra was tested according to the following FDA-recognized consensus standards:
- IEC 60601-1-2, Issue: 2014/02/25 Ed:4.0 (Equivalent to AAMI/ANSVIEC 60601-● 1-2:2014) "Medical Electrical Equipment - Part 1-2: General Requirements for Basic Safety and Essential Performance -Collateral Standard: Electromagnetic disturbances - Requirements and Tests." Results demonstrated that the device is compliant to this standard.
- . AAMI/ANSI ES60601-1:2005/(R)2012 and C1:2009/(R)2012 and, A2:2010/(R)2012 "Medical Electrical Equipment; Part 1: General requirements for basic safety and essential performance."
- . IEC 60601-1-11:2015 "Medical electrical equipment: General requirements for basic safety and essential performance – Collateral Standard: Requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment."
- . IEC 60601-2-10: 2012 and A1:2016 "Medical Electrical Equipment Part 2-10: Particular requirements for the basic safety and essential performance of nerve and muscle stimulators."
SOFTWARE
A failure in the software of the Nerivio Migra could indirectly result in patient injury; therefore, the software of this device is considered to have a "Moderate" level of concern.
The submission contained all the elements of software documentation corresponding to a "Moderate" level of concern, as outlined in the FDA guidance document "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." Adequate documentation describing the software, firmware, software specifications, architecture design, software development environment, traceability, revision level history, unresolved anomalies and cybersecurity provides the foundation that the software will operate in a manner as described in the specifications. A hazard analysis was performed to characterize software risks including device malfunction and measurement related errors. The submission included verification and validation (V&V) testing to address the potential hazards with satisfactory results.
5
ADDITIONAL PERFORMANCE TESTING
The following additional testing was performed:
● Wireless Coexistence Testing
The device hardware communicates with the mobile application through a Bluetooth protocol and it is intended to be used in the home environment. Thus, a wireless Quality of Service and corresponding wireless coexistence testing was provided per with the FDA Guidance: Radio Frequency Wireless Technology in Medical Devices. Results demonstrated that the system meets specifications.
Lithium-Ion Battery Testing ●
The Nerivio Migra is powered by a Lithium-Ion battery AE503759P6H, 3.7V, 1.2 Ah. The battery is internal, integrated inside an enclosure, and cannot be charged or accessed by the user. The battery is charged outside of the device at the time of the device's manufacturing, then placed inside the enclosure of the device, which is sealed. The battery complies with the UL-1642 (Standard for Lithium batteries), IEC 62133-2 (Standard for lithium batteries), and IEC 60601-1 (Basic Safety).
● Electrical Stimulation Output Characterization:
Testing was performed to characterize the stimulation output waveform, the functionality of the Nerivio Migra as a system, and the requirements of the output stimulation parameters. Results demonstrated that the system meets specifications.
Electrode Bench Testing: .
Testing was performed to assess the mechanical measurements, the design of the electrodes (and tolerances) and the electrical characteristics (impedance and current distribution) of the electrodes under the expected worst-case conditions of normal operation. Results demonstrated that the electrodes passed all testing.
SUMMARY OF CLINICAL INFORMATION
Study Overview
The 252-subject pivotal study was a prospective, one-to-one randomized, double-blind, sham controlled multi-center study to evaluate the effectiveness and safety of Nerivio Migra. The neurostimulation amplitude for the treatment group was based on each subject's stimulation threshold. The sham group received different, "no-activation pseudo-amplitude" stimulation. which reached the subject's stimulation threshold. The study site personnel and investigator were blinded to the subject's therapy allocation. Subjects recorded migraine severity before treatment, 2 hours and 48 hours following the treatment using various metrics. Safety was assessed using adverse event data collected during the study.
6
Inclusion Criteria
- Subjects age 18 through 75 years of age 1.
- Subjects meet the ICHD-3 diagnostic criteria for migraine with or without aura 2.
-
- Subjects report 2-8 migraine attacks per month.
- No change in usage or dosage of migraine preventive medications for two months prior to 4. study entry.
-
- Subjects must be able and willing to comply with the protocol.
- Subjects must be able and willing to provide written informed consent. 6.
Exclusion Criteria
-
- Subject has other significant pain, medical or psychologic problems that in the opinion of the investigator may confound the study assessments
-
- Subject has an implanted electrical or neurostimulation device. These devices include a cardiac pacemaker or defibrillator, vagus nerve neurostimulator ,deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, sphenopalatine ganglion stimulator or occipital nerve stimulator.
- Subject has known uncontrolled epilepsy. 3.
-
- Any use of Cannabis including medical use
-
- Subject has more than 12 headache days per month.
- Subject has undergone nerve block (occipital or other) in the head or neck within the last 2 6. weeks.
-
- Participant is participating in any other clinical study.
-
- The participant does not have the basic cognitive and motor skills needed to operate a smartphone.
-
- Pregnant, or trying to get pregnant or lactating women.
-
- Female subject experiencing only menstrual related migraines during menstrual period only).
-
- Received any botulinum toxin injections for migraine within the previous month.
-
- Received parenteral infusions for migraine within the previous 2 weeks.
-
- Participant participated in a previous study with the Nerivio Migra device.
Study Endpoints
Safety:
Adverse event types and rates for all enrolled subjects.
Effectiveness:
The primary outcome measure was the percentage of participants reporting a reduction in their pain level without use of medication from severe or moderate to mild or no pain or from mild to no pain within 2 hours in the "test treatment" excluding the run-in treatment which was the first in-study migraine attack.
The secondary effectiveness outcome measures are the proportion of participants who did not take medications and reported:
7
-
- A reduction in their most bothersome symptom (MBS) at 2 hours post-treatment. MBS may be nausea, photophobia, or phonophobia- as defined by each participant at the beginning of the treatment.
- A reduction in pain and their MBS at 2 hours post-treatment 2.
-
- Freedom from pain at 2 hours post-treatment
-
- Freedom from their MBS at 2 hours post-treatment.
Protocol (study design)
The 252-subject study included three phases: Phase One - Roll In, Phase Two - Parallel arm, double-blind treatment phase, and Phase Three - Optional Open-label extended treatment.
In the first ("roll-in") phase, participants were asked to keep a headache diary for one month in which all migraines were documented. Eligible participants were trained to use the smartphone migraine diary application for up to one month. Only participants who properly reported at least 2 and no more than 8 migraine attacks continued to the next phase.
The second phase was a double-blind treatment phase, in which eligible participants were randomly allocated in a 1:1 ratio to either active stimulation (treatment group) or sham pseudostimulation (sham group). All participants underwent training on how to use the device and how to use the diary and feedback application. During this training, an optimal individual stimulation intensity level ("well perceived but not painful") was identified for each participant (treatment and sham). Participants in both groups were then asked to treat their migraines for 6 weeks, or up to 4 qualified migraine attacks, using the device with the identified stimulation intensity (±5%). Participants were asked to treat each migraine within 60 minutes of symptom onset. The participants used the application to record pain scores at baseline, 2 hours post-treatment and 48 hours post-treatment, to record the presence/absence of associated migraine symptoms (nausea, photophobia, phonophobia), to define their Most Bothersome Symptom (MBS) prior to each treatment and to record if there is a relief in their MBS following the treatment. The first reported treatment was considered a "run-in test" treatment, aimed to verify the participants use the device properly, and was only included in the safety analysis. The effectiveness evaluation was performed on the first fully treated (30-45 minutes) attack with 2 hours post-treatment assessment following the "run-in test" treatment (hereby termed test treatment).
Phase Three was an optional, open-label extension phase. Following the completion of doubleblind treatment phase of the study, all participants were offered to participate in a 2-month openlabel period using an active device.
Sham Design
The sham device produced a perceptible signal, in which the sponsor implemented pseudo-random pulses, which have a relatively long duration in order to generate an "electrical sensation" for the participant and enable him/her to adjust the intensity as done in the active program.
Overall, both the active and the sham devices generated a similar sensation. Participants did not distinguish between the treatment and sham device.
8
The first time participants were introduced to the device was in the randomization visit. which occurred after the "roll-in" phase. During the "roll-in" phase, the participants only used the mobile application (without the device) to report their migraine attacks.
Statistical Analysis Plan (SAP)
- . Analysis sets
-
- Intent to treat analysis set (ITT)
-
The ITT analysis set included all participants who were randomized. In accordance with the ITT principle, all participants randomized were kept in their originally assigned group.
2. Modified intend to treat analysis set (mITT)
The mITT analysis set included all participants who were randomized and treated at least one attack (excluding the run-in test attack) within 1 hour from the attack onset.
- Per-protocol analysis set (PP)
The PP analysis set included participants who were randomized and for whom the first qualified attack (excluding the "run-in" test attack) conformed with the protocol instructions:
- . The treatment starts within one hour from attack onset.
- . No rescue medication (or pain medication) is consumed within 2 hours after start of treatment.
- . The treatment was not stopped early (i.e., before the first 30 minutes).
- No pain medication consumption 24 hours prior to the onset of the migraine ●
- Statistical analysis of the analysis sets:
- The ITT analysis set served as the main set for safety assessments 1.
-
- The mITT analysis set was used for all effectiveness assessments.
- The primary and secondary effectiveness assessments were performed on the mITT 3. analysis set and also on the PP and ITT analysis sets as a sensitivity analysis to assess the effect of protocol deviation and discontinuations
- Safety Analysis ●
Adverse event (AE) rates were presented on all enrolled subjects, overall as well as by treatment group. The rates of events and type were presented and compared between groups using the Fisher's Exact test.
- Blinding Assessment
The success of the blinding of subjects was assessed at the end of the study visit using a blinding assessment questionnaire. Subjects were asked whether they thought they were in the active or sham group or if they did not know using a three-point scale (active, sham or I don't know).
9
- Effectiveness analysis ●
Primary effectiveness analyses:
The primary outcome measure was the proportion of participants with a decrease in headache pain from severe or moderate to none or mild to no pain within 2 hours in the test treatment. The percentage of participants reporting such headache pain reduction without rescue medications was assessed in both study groups and was compared using a chi-squared test and a Fisher's exact test.
Secondary effectiveness analyses:
The secondary effectiveness variables were compared with a chi-squared test and a Fisher's exact test.
Study Results
- Subject Disposition
A total of 296 participants were recruited to the study, 252 participants were randomized at the end of the roll-in phase. Of these, 126 eligible participants were randomly assigned to receive active Nerivio Migra device (active group) and 126 were randomly assigned to receive sham Nerivio Migra device (sham group). Among the 252 randomized participants, 7 participants withdrew from the study (4 in the active group and 3 in the sham group); 3 participants (1 from the sham group and 2 from the active group) withdrew from the study due to intolerance to the sensation of the stimulation (two participants withdrew during the randomization visit after the training, so the devices were never used at home), and 4 participants (2 in the active group and 2 in the sham group) were lost to follow up. A total of 237 participants completed at least one treatment (the run-in treatment) and 202 participants completed the test treatment within one hour from symptom onset and reported a pain level at 2 hours (Figure 1). A modified intent to treat (mITT) group was defined as all randomized subjects who treated at least one attack (excluding the "run-in test" attack) within 1 hour from the attack onset.
10
Image /page/10/Figure/0 description: This image is a flowchart that shows the progress of participants through a study. The study starts with 296 participants enrolled, and 44 are not eligible or withdraw. The remaining 252 participants are randomized into two groups, with 126 in each group. The final set includes 103 in the sham group and 99 in the active group.
Figure 1: Participant disposition
- Subject Demographics ●
The majority of participants were female (80.7%), and the mean age was 42.7±12.06 years. The demographic characteristics were generally similar among treatment groups (Table 2) and comparable to those reported in previous migraine studies. Migraine history and characteristics of the active and sham groups were comparable (Table 3).
| All | Active | Sham | Nominal | ||
|---|---|---|---|---|---|
| P value | |||||
| Gender | Male | 19.4% (49/252) | 19.8% (25/126) | 19.0% (24/126) | 0.9753 |
| Female | 80.6% (203/252) | 80.2% (101/126) | 81.0% (102/126) | ||
| Caucasian** | 87.7% (221/252) | 86.5% (109/126) | 88.9% (112/126) | 0.6595 | |
| Race | American Indian | ||||
| or Alaskan | 0% | 0% | 0% | ||
| Asian | 0.8% (2/252) | 1.6% (2/126) | 0% | ||
| African- | |||||
| American | 7.1% (18/252) | 8.1% (10/124) | 6.3% (8/126) | ||
| Native Hawaiian | 0.8% (2/252) | 0.8% (1/126) | 0.8% (1/126) | ||
| African Arab or | |||||
| Eastern Arabs | 1.2% (3/252) | 1.6% (2/126) | 0.8% (1/126) | ||
| Other | 2.4% (6/252) | 1.6% (2/126) | 3.2% (4/126) | ||
| N | 252 | 126 | 126 | 0.1462 | |
| Age | Mean (SD) | 42.7 (12.06) | 43.8 (12.25) | 41.6 (11.81) | |
| Median [range] | 41.8 [18.5; 70.1] | 43.5 [18.5; 70.1] | 40.8 [19.3; 66.9] | ||
| N | 250 | 124 | 126 | 0.9730 | |
| Height | Mean (SD) | 166.4 (9.00) | 166.4 (9.46) | 166.4 (8.56) | |
| Median [range] | 165.1 [130; 190] | 165.1 [130; 190] | 165.6 [147; 185] | ||
| N | 252 | 126 | 126 | 0.8182 | |
| Weight | Mean (SD) | 75.4 (18.79) | 75.1 (20.47) | 75.6 (17.03) | |
| Median [range] | 72.2 [39.0; 160.0] | 71.7 [39.0; 160.0] | [46.0; 142.0] |
Table 2: Demographic characteristics (ITT)
11
| | | All | Active | Sham | Nominal
P value |
|---------------------------------|------------------|-----------------|-----------------|-----------------|--------------------|
| Average Number | N | 251 | 126 | 125 | 0.8505 |
| of Attacks per | Mean (SD) | 5.3 (1.92) | 5.2 (1.95) | 5.3 (1.90) | |
| Month | Median [range] | 5.0 [2.0; 9.0] | 5.0 [2.0; 8.0] | 5.0 [2.0; 9.0] | |
| Average number of | N | 251 | 126 | 125 | 0.9559 |
| migraine days per | Mean (SD) | 6.6 (2.40) | 6.6 (2.43) | 6.6 (2.41) | |
| month | Median (range) | 7.0 [2.0;12.0] | 7.0 [2.0; 12.0] | 7.0 [2.0; 12.0] | |
| Use of preventive
medication | | 32.8% (82/250) | 28.6% (36/126) | 37.1% (46/124) | 0.1511 |
| aura preceding a | None | 50.2% (125/249) | 49.6% (62/125) | 50.8% (63/124) | 0.6639 |
| migraine attack | Rarely | 22.5% (56/249) | 20.8% (26/125) | 24.2% (30/124) | |
| | Often | 27.3% (68/249) | 29.6% (37/125) | 25.0% (31/124) | |
| | 0-2h | 2.4% (6/250) | 3.2% (4/125) | 1.6% (2/125) | 0.3665 |
| Average attack | 2-6h | 8.8% (22/250) | 9.6% (12/125) | 8.0% (10/125) | |
| duration without | 6-12h | 14.8% (37/250) | 10.4% (13/125) | 19.2% (24/125) | |
| medication | 12-24h | 18.8% (47/250) | 21.6% (27/125) | 16.0% (20/125) | |
| | 24-48 | 28.4% (71/250) | 29.6% (37/125) | 27.2% (34/125) | |
| | >48h | 26.8% (67/250) | 25.6% (32/125) | 28.0% (35/125) | |
| | Always | 71.3% (179/251) | 72.2% (91/126) | 70.4% (88/125) | 0.9767 |
| Use of acute | Sometimes | 24.3% (61/251) | 23.8% (30/126) | 24.8% (31/125) | |
| medication | Rarely | 2.8% (7/251) | 2.4% (3/126) | 3.2% (4/125) | |
| | Never | 1.6% (4/251) | 1.6% (2/126) | 1.6% (2/125) | |
| | 0-2h | 36.4% (90/247) | 36.3% (45/124) | 36.6% (45/123) | 0.7547 |
| Average attack | 2-6h | 36.4% (90/247) | 35.5% (44/124) | 37.4% (46/123) | |
| duration with | 6-12h | 8.5% (21/247) | 8.9% (11/124) | 8.1% (10/123) | |
| medication | 12-24h | 7.3% (18/247) | 8.1% (10/124) | 6.5% (8/123) | |
| | 24-48 | 6.5% (16/247) | 4.8% (6/124) | 8.1% (10/123) | |
| | >48h | 4.9% (12/247) | 6.5% (8/124) | 3.3% (4/123) | |
| | None | 2.0% (5/250) | 3.2% (4/125) | 0.8% (1/125) | 0.0617 |
| | Nausea | 27.2% (68/250) | 29.6% (37/125) | 24.8% (31/125) | |
| Most bothersome | Light | 50.0% (125/250) | 43.2% (54/125) | 56.8% (71/125) | |
| migraine symptom | Sound | 19.2% (48/250) | 20.8% (26/125) | 17.6% (22/125) | |
| beyond pain | Skin Sensitivity | 1.6% (4/250) | 3.2% (4/125) | 0% (0/125) | |
Table 3: Migraine history
. Safety endpoint
Safety analyses were performed on all 252 participants from the ITT population. 773 treatments were performed during the study (including the run-in treatment). The percentage of participants with at least 1 adverse event (regardless of its suspected cause) was 13.5% (34/252) and was comparable across treatment groups (15.1% (19/126) in the active group and 11.9% (15/126) in the sham group, prister's=0.5807). The incidence of device-related adverse events was low (3.6%), and similar between treatment groups (active group: 6/126 [4.8%]; sham group: 3/126 [2.4%]; prishers=0.4998). Notably, there were no unanticipated adverse device effects.
23 device-related adverse events were reported during 773 treatments (2.7%), 14 in the active group and 9 in the sham group. All device-related adverse events reported were mild in severity, did not require treatment and were resolved. No serious adverse events related to the device were reported. No statistically significant differences were found between treatment groups in either the type or rate of adverse events during the double-blind treatment phase (Table 4).
12
| All | Active | Sham | |
|---|---|---|---|
| Sensation of warmth | 9/773 (1.2%) | 6/385 (1.6%) | 3/388 (0.8%) |
| Numbness of the arm/hand | 2/773 (0.2%) | 2/385 (0.5%) | 0/388 (0%) |
| Redness | 3/773 (0.4%) | 2/385 (0.5%) | 1/388 (0.3%) |
| Itching | 1/773 (0.1%) | 1/385 (0.2%) | 0/388 (0%) |
| Neck and shoulder pain | 2/773 (0.2%) | 0/385 (0%) | 2/388 (0.8%) |
| Pain in the arm | 2/773 (0.2%) | 2/385 (0.5%) | 0/388 (0%) |
| Tingling | 3/773 (0.4%) | 0/385 (0%) | 3/388 (0.8%) |
| Muscle spasm | 1/773 (0.1%) | 1/385 (0.2%) | 0/388 (0%) |
Table 4: TCH-003 Device-related adverse events
● Primary effectiveness outcome
In the mITT analysis set (i.e., all participants who were randomized and treated at least one attack [excluding the run-in test attack] within 1 hour from the attack onset), the proportion of participants achieving a pain-reduction response 2 hours after treatment in the test treatment was 66.7% (66/99) in the active group compared with 38.8% (40/103) in the sham group (therapeutic gain 27.9%; pchi-squared